Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
September 01, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...
aTyr Pharma to Present at March Investor Conferences
February 25, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
H.C. Wainwright reiterates ‘Buy’ for Co-Diagnostics (NASDAQ:CODX) with a $35 Price Target as COVID-19 Surge Boosts Testing Demand
July 14, 2020 07:30 ET
|
BDA International
New York City, July 14, 2020 (GLOBE NEWSWIRE) -- Analyst Yi Chen of H.C. Wainwright & Co. reiterated his ‘buy’ coverage on Co-Diagnostics (NASDAQ:CODX), the Utah-based molecular diagnostics...
Co-Diagnostics (NASDAQ:CODX) Analysts Set Price Target Between $30 and $36
May 28, 2020 09:00 ET
|
BDA International
New York City, May 28, 2020 (GLOBE NEWSWIRE) -- Analysts from H.C. Wainwright, Maxim Group and Litchfield Hills have all upgraded or reiterated Co-Diagnostics (NASDAQ: CODX) as “Buy” rating in the...
Co-Diagnostics (NASDAQ:CODX) Reiterated Buy; Joins Distinguished Group Racing to Meet Unprecedented Global Demand for COVID-19 Testing
March 25, 2020 11:30 ET
|
BDA International
NEW YORK CITY, March 25, 2020 (GLOBE NEWSWIRE) -- The global shortage of COVID-19 testing kits is hitting the United States and other nations hard, but a recent FDA policy change means that...
Buy for Co-Diagnostics (NASDAQ:CODX) Reiterated by H.C. Wainwright with $20 Price Target
March 11, 2020 09:30 ET
|
BDA International
New York City, March 11, 2020 (GLOBE NEWSWIRE) -- Analyst Yi Chen released additional coverage on Co-Diagnostics (NASDAQ:CODX), a Utah-based molecular diagnostics company, raising the firm’s price...
H.C. Wainwright Reiterates Buy Rating for Co-Diagnostics (NASDAQ:CODX) Following News of Expansion into Africa
October 31, 2019 07:00 ET
|
BDA International
New York, Oct. 31, 2019 (GLOBE NEWSWIRE) -- H.C. Wainwright has reiterated their “Buy” rating for Co-Diagnostics, Inc. (Nasdaq: CODX), a biotech with a patented platform for the development of...
INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & CO.
August 27, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...